Canaccord lowered the firm’s price target on 2seventy Bio to $11 from $12 and keeps a Buy rating on the shares. The firm said the company expects ABECMA revenues to begin growth 2H24, due to expansion into 3rd-line Multiple Myeloma. Competition with bispecifics and CARVYKTI will continue, although bispecifics are not yet approved in the 3rd-line setting.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSVT:
- 2seventy Bio price target raised to $12 from $9 at Citi
- 2seventy bio’s Abecma Wins FDA Approval for Multiple Myeloma
- Bristol Myers, 2seventy Bio’s Abecma approved by U.S. FDA
- Fly Insider: 2seventy bio, Coinbase among week’s notable insider trades
- 2seventy bio Finalizes Asset Sale and Executive Transition
Questions or Comments about the article? Write to editor@tipranks.com